Our Partners

We have established numerous strategic collaborations to increase our pipeline of assets, explore new treatment areas, and advance our oncology programs to broaden the patient populations we serve.


China Partners

Apollomics Partners_pearl
Beijing Pearl Biotechnology Co. Ltd. has development and commercialization rights in China for APL-101 where it is referred to as PLB1001.
Apollomics Partners_Bossan
Zhejiang Bossan Pharmaceutical Co., Ltd. has development and commercialization rights in China for APL-103 where it is referred to as ES-072.
Apollomics Partners_genor
Genor BioPharma Co. Ltd. has development and commercialization rights in China for APL-501 where it is referred to as GB226.
Apollomics Partners_chia tai
Chia Tai TianQing Pharmaceutical Group (CTTQ Pharma) has development and commercialization rights in China for APL-502 where it is referred to as TQ-B2450.

Development Partners

Apollomics Partners_strata
Strata’s genomic screening protocol will drive patient enrollment in CBT’s ongoing Phase 1/2 trial of APL-101.
Apollomics Partners_cg
Co-development commercialization of the combination of CBT-501 and CG200745 in multiple tumor types.